Ooops... Something went wrong while loading this page.

Earnings call Cytokinetics transitioned to a global commercial-stage company in Q4 2025, driven by the FDA, EU, and China approvals and U.S. launch of MYQORZO. Full-year 2025 revenue surged to $88M ...